Advertisement

Pointers to Cancer Prognosis

  • Basil A. Stoll

Part of the Developments in Oncology book series (DION, volume 48)

Table of contents

  1. Front Matter
    Pages I-XII
  2. Clinical pointers to prognosis

    1. Front Matter
      Pages 1-1
    2. S. P. Parbhoo
      Pages 3-19
    3. P. R. Clingan, N. F. Boyd
      Pages 20-36
    4. A. H. G. Paterson
      Pages 37-48
    5. J. Rosenman, M. Varia
      Pages 49-64
    6. M. Harding, S. B. Kaye
      Pages 65-78
  3. Biological pointers to prognosis

    1. Front Matter
      Pages 89-89
    2. J. D. Crissman, R. J. Zarbo
      Pages 110-123
    3. E. J. Ormerod, I. R. Hart
      Pages 124-142
    4. M. R. Schwartz, W. B. Panko
      Pages 143-155
    5. L. Levin, J. F. Harris, A. F. Chambers
      Pages 156-170
    6. K. P. Ryan, R. O. Dillman
      Pages 171-192
  4. Clinical application of prognostic indices

    1. Front Matter
      Pages 193-193
    2. B. A. Stoll
      Pages 195-229
    3. A. J. Dembo, G. M. Thomas, M. L. Friedlander
      Pages 230-250
    4. G. Williams
      Pages 251-265
    5. M. H. Rosen, A. P. Chahinian
      Pages 266-286
    6. R. J. Zarbo, J. D. Crissman
      Pages 287-305
    7. S. J. Arnott
      Pages 306-321
    8. J. L. Craven
      Pages 322-332
    9. M. A. Richards, W. M. Gregory, T. A. Lister
      Pages 333-357
  5. Back Matter
    Pages 359-368

About this book

Introduction

The last 30 years have seen little improvement in the age-adjusted mortality rates for most common types of cancer, and until we develop more effective and less damaging treatment modalities for these tumours, selection of each patient's treatment must depend on prognostic pointers. These lead to a calculated trade­ off between our estimate of likely benefit to the patient, as against cost in terms of quality of life. But changes have occurred recently in our understanding of the traditional prognostic pointers used for selecting such individualised treatment. First, it is increasingly recognised that the stage at which a tumour presents is more related to the chromo logical age of the tumour (how far it has progressed before diagnosis) than to its biological characteristics. While advanced chronological age of the tumour may predict a greater likelihood of early death, only biological criteria can predict the tumour growth rate, the likelihood of prolonged survival, the likely course of the disease after the first recurrence or the likehood of response to systemic therapy. Second, there is increasing use of failure analysis in relating the clinical and biological characteristics of tumours to their response to standard treatments. In the past, the relationship was interpreted mainly in terms of survival rate, but the site and timing of first recurrence and the pattern and timing of subsequent spread provide a better assessment of the control possible from local or systemic therapy.

Keywords

Staging histopathology lymphoma metastasis pathology

Editors and affiliations

  • Basil A. Stoll
    • 1
  1. 1.Honorary consultant physician to Oncology DepartmentsSt. Thomas’ Hospital and Royal Free HospitalLondonUK

Bibliographic information

  • DOI https://doi.org/10.1007/978-94-009-3291-3
  • Copyright Information Springer Science+Business Media B.V. 1987
  • Publisher Name Springer, Dordrecht
  • eBook Packages Springer Book Archive
  • Print ISBN 978-0-89838-876-3
  • Online ISBN 978-94-009-3291-3
  • Buy this book on publisher's site